#United States #San Diego #Class Action #Robbins LLP #Mereo BioPharma

Robbins LLP Draws Attention to Class Action Lawsuit Against Mereo BioPharma

Robbins LLP has recently brought to light a class action lawsuit that may affect numerous investors who acquired shares of Mereo BioPharma Group plc (NASDAQ: MREO). This legal action has been initiated on behalf of stockholders who purchased shares between June 5, 2023, and December 26, 2025. Mereo is primarily engaged in the biopharmaceutical sector, focusing on developing therapeutic solutions aimed at addressing rare diseases.

Background of the Case

The crux of the lawsuit revolves around allegations that Mereo BioPharma misled investors regarding the results of their Phase 3 clinical studies, specifically the ORBIT and COSMIC studies concerning the drug setrusumab, which is intended for the treatment of Osteogenesis Imperfecta (OI). The plaintiff's complaint outlines that executives from Mereo made optimistic statements about their studies that misrepresented their chances of success and concealed adverse realities regarding the data that emerged from these trials.

Investors were reassured about setrusumab’s potential to reduce fracture rates significantly in patients. However, it was later revealed that both the ORBIT and COSMIC studies did not meet their primary endpoints, causing considerable financial losses for investors who had acted on the misleading information.

On December 29, 2025, Mereo released a statement conceding that neither study achieved the desired result of reducing annualized clinical fracture rates compared to control groups. Following this announcement, Mereo's stock price plummeted from $2.31 to a mere $0.29 per share, witnessing a staggering decline of over 87.7%.

What Investors Should Do

Shareholders of Mereo BioPharma who believe they were impacted by these developments may have the opportunity to participate in the ongoing class action lawsuit. Those interested in taking on the role of lead plaintiff should reach out to Robbins LLP for further guidance. A lead plaintiff is a designated individual who represents the interests of all other affected shareholders and directs the course of the litigation. However, it's worth noting that participation in this case is not required to qualify for any potential recovery.

Should you elect to remain passive, your status as an absent class member remains intact. Robbins LLP operates on a contingency fee basis, ensuring that shareholders will not incur any fees unless they secure a favorable outcome.

About Robbins LLP

Established in 2002, Robbins LLP has built a reputation as a dedicated advocate for shareholders' rights. The firm specializes in ensuring that investors who experience losses due to corporate misconduct can recover their funds while also promoting better corporate governance.

In addition, Robbins LLP provides resources and alerts for individuals looking to be informed about settlements and corporate executive malfeasance. Interested parties can easily sign up for their notification service called Stock Watch to stay updated on relevant news that could affect their investments.

This class action lawsuit against Mereo BioPharma Group plc is an important reminder for investors to remain vigilant and informed about the companies they invest in, especially when it comes to disclosures related to clinical trials and research studies. For more information or to assess your eligibility to join the lawsuit, you can reach out to Robbins LLP directly at (800) 350-6003 or fill out a submission form as instructed in their announcements.